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Research Article
Propofol produces preventive analgesia via
GluN2B-containing NMDA receptor/ERK1/2
signaling pathway in a rat model of
inflammatory pain
Qiu Qiu1,2,*, Liting Sun1,2,*, Xiao Min Wang1,2, Amy CY Lo3,
Kar Lok Wong4, Pan Gu1,2, Sau Ching Stanley Wong1 and
Chi Wai Cheung1,2
Abstract
Propofol, an intravenous anesthetic, has been shown to offer superior analgesic effect clinically. Whether propofol has preventive
analgesic property remains unexplored. The present study investigated the antinociceptive effect of propofol and underlying
molecular and cellular mechanisms via pre-emptive administration in a formalin-induced inflammatory pain model in rats. Male
adult Sprague–Dawley rats were randomly allocated into four groups: naı¨ve (Group Naı¨ve), formalin injection only (Group
Formalin), and formalin injection at 30 min (Group P-30 min) or 2 h (Group P-2 h) after intravenous infusion of propofol
(0.6 mg kg1min1) for 1 h. Nociceptive responses and protein expression of phosphorylated- or pan-GluN2B, ERK1/2, p38
mitogen-activated protein kinase, and c-Jun N-terminal kinase in the spinal dorsal horn were evaluated. Alteration of intracellular
Ca2þ concentration induced by N-methyl-D-aspartate (NMDA) receptor agonists with or without pre-treatment of propofol was
measured using fluorometry in SH-SY5Y cells while neuronal activation in the spinal dorsal horn by immunofluorescence. Pre-
emptive propofol reduced pain with a delayed response to formalin and a reduction in hypersensitivity that lasted at least for 2 h.
The formalin-induced activation of spinal GluN2B and ERK1/2 but not p38 or c-Jun N-terminal kinase was also diminished by
propofol treatment. Preconditioning treatment with 3mM and 10mM of propofol inhibited Ca2þ influx mediated through NMDA
receptors in SH-SY5Y cells. Propofol also reduced the neuronal expression of c-Fos and p-ERK induced by formalin. This study
shows that pre-emptive administration of propofol produces preventive analgesic effects on inflammatory pain through regulating
neuronal GluN2B-containing NMDA receptor and ERK1/2 pathway in the spinal dorsal horn.
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Introduction
The role of anesthetics in nociceptive processing has long
been of interest in anesthesiology. Propofol, a commonly
used general anesthetic for induction and maintenance of
general anesthesia (i.e. total intravenous anesthesia,
TIVA) during surgical procedures,1 has been reported
to have analgesic property in management of acute post-
operative pain as compared with other anesthetics.2,3
However, the ﬁndings from clinical or pre-clinical studies
are widely varied from analgesia,4,5 no analgesia,6,7 or
even hyperalgesia.8 The natures of noxious stimulation
and administration timing of propofol, e.g., pre- versus
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post-noxious stimulation play roles in these discrepant
results.6,8,9
Spinal N-methyl-D-aspartate (NMDA) receptors
were reported to be involved in the antinociceptive
eﬀect of propofol.10 Distinct from its GABAergic mech-
anism underlying its general anesthetic properties, the
inhibitory eﬀects of propofol on NMDA receptor11
and calcium ion currents in primary aﬀerent neurons12
may play an essential role in the analgesic property of
propofol. NMDA receptors, widely existing in the cen-
tral nervous system, play critical roles in generation and
maintenance of central sensitization associated with
hyperalgesia and allodynia in the spinal cord.13 GluN2
receptor, a subunit of NMDA receptors, includes four
types of GluN2A, 2B, 2C, and 2D. Among them,
GluN2B subtype dominates at synapses of lamina I
in adult spinal dorsal horn and is involved in diversiﬁed
pain processing via mediating nociceptive signal trans-
mission in the spinal cord.14–17 For instance, in
the animal model of formalin-induced inﬂammatory
pain, GluN2B exhibited highest expression in the spinal
cord compared to other NMDA subunit receptors.18
Moreover, propofol was found to produce antinocicep-
tion in hot-plate test and acetic acid-induced
writhing test in mice through interaction with spinal
NMDA receptor.19 Therefore, GluN2B-containing
NMDA subunits may contribute to the analgesic
action of propofol.
Mitogen-activated protein kinases (MAPKs) family,
including extracellular signal-regulated kinase1/2
(ERK1/2), p38 MAPK, and c-Jun N-terminal kinase
(JNK), transduces a wide range of extracellular stimuli
into various intracellular responses by transcriptional or
non-transcriptional regulation.20 Accumulating evidence
shows that the activation of MAPKs in both neurons
and glia cells involves in the induction and maintenance
of pain hypersensitivity under diﬀerent types of pain con-
ditions.21 MAPKs activation can be blocked by NMDA
receptor antagonists in vivo and in vitro and that blocks
the noxious-signal transmission induced by ERK activa-
tion consequently.22–26
Pre-emptive analgesia that modulates sensory input
before surgery has been widely used as an analgesic strat-
egy to manage post-surgical pain by preventing or sup-
pressing spinal mechanisms of neuronal sensitization.27
Pre-emptive single dose of intravenous propofol was
found to reduce post-surgical analgesia requirements in
comparison with ketamine or remifentanil clinically.9
Inﬂammatory pain is the most often post-surgical
sequela partially due to tissue injury and release of
inﬂammatory mediators.28 In this study, using the well-
established inﬂammatory pain model induced by forma-
lin injection and adopting the same modality used in
clinical administration by intravenous infusion of
propofol, we attempted ﬁrst to investigate whether pro-
pofol infused before inﬂammation challenge possesses
preventive analgesic eﬀects on inﬂammatory pain;
second to evaluate whether GluN2B subunit-containing
NMDA receptor and downstream of MARK cascades
play a role in the analgesic property of propofol at the
spinal cord level following inﬂammatory pain; and
ﬁnally, to identify the cellular mechanisms underlying
its preventive analgesic eﬀect at the spinal dorsal horn
level.
Materials and methods
Animals
Male adult Sprague–Dawley rats weighing approxi-
mately 250–300 g were used throughout the study. Rats
were housed in cages with ad libitum food and water on a
standard 12:12 h light/dark cycle. Animal experiments
were conducted by animal license holders authorised by
Department of Health, The Government of Hong Kong
Special Administrative Region and approved by the
Committee on the Use of Live Animals in Teaching
and Research (CULATR, reference number #3383–14)
at the University of Hong Kong. Rats were euthanatized
by overdose of sodium pentobarbital (Virbac, Milperra,
Australia) by intraperitoneal injection followed by cer-
vical decapitation after all the experiments.
Experimental design
Rats were randomly divided into four groups using an
online software (www.randomization.com): Naive group
without any treatment (Group Naı¨ve), formalin treat-
ment group with formalin injection only (Group
Formalin, MilliporeSigma, St. Louis, MO, USA), and
formalin injection with pretreatment of propofol fol-
lowed by a recovery time of 30min (Group P-30min)
or 2 h (Group P-2 h). In the groups with pretreatment
of propofol, rats received 0.6mg kg1min1 of propofol
(B. Braun, Melsungen, Germany) via tail vein for 1 h.
Prior to formalin injection, either 30min or 2 h recovery
time was allowed for animals to recover from the anes-
thetic eﬀect of propofol for Group P-30min and Group
P-2 h, respectively. The animals that did not conform to
the recovery criteria, based on the modiﬁed system for
post-anesthesia recovery scoring, were eliminated from
this study.29
Formalin-induced inflammatory pain
At 30min or 2 h after propofol infusion, inﬂammatory
pain was induced by injection of 50 ml of 2.5% formalin
solution (MilliporeSigma) into the plantar of right hind
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paw using a 30-gauge, ultra-ﬁne needle (Becton,
Dickinson and Company, NJ, USA). Pain severity was
evaluated using the composite pain score- weighted
scores technique 0,1,2 time (Composite pain score
[CPS]-WST0,1,2) after the injection of formalin.
30 Rats
were housed individually in plexiglass chambers on a
metal mesh for acclimation to the chamber, and obser-
vation of the animal’s behavior was made in consecutive
5-min periods for 60min after formalin administration.
In each 5-min period, the total time the animal spent in
three diﬀerent behavioral categories was recorded: (1)
the injected paw had little or no weight placed on it;
(2) the injected paw was raised; and (3) the injected
paw was licked, shaken, or bitten. The CPS was calcu-
lated according to the following formula
CPS ¼ 1 time in category 2ð Þþ 2 time in category 3ð Þ
300 sð Þ
To avoid experimental bias, the tester was blind to the
study groups.
Western blot
In another cohort of animals with identical treatment, at
25min after the injection of formalin when the pain sen-
sitivity reached peak, both ipsilateral and contralateral
dorsal horns of lumbar spinal cord (from segments L3 to
L5) were dissected after a laminectomy under deep anes-
thesia of isoﬂurane (Abbott Laboratories, Berkshire,
UK). The dorsal horn sample was homogenized in
ice-cold Laemmli buﬀer containing 50mM Tris-HCl,
pH7.5, 0.5% sodium dodecyl sulfate (SDS), 5%
2-mercaptoethanol, and 1% protease inhibitor cocktail
(MilliporeSigma). The proteins were separated on
SDS-polyacrylamide gel electrophoresis and then trans-
ferred to polyvinylidene diﬂuoride membranes.
Membranes were then incubated with diﬀerent primary
antibodies including phosphorylated or pan-GluN2B
(Merck Millipore, Darmstadt, Germany), ERK1/2, p38
MAPK, JNK (Cell Signaling Technology, Danvers, MA,
USA), and the loading control glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH; Merck Millipore,
Darmstadt, Germany) separately overnight at 4C.
Membranes were then incubated with goat anti-rabbit
IgG (Cell Signaling Technology, Danvers, MA, USA)
or goat anti-mouse IgG for 1 h at room temperature.
Proteins were detected by enhanced chemiluminescence
(Bio-Rad Laboratories, Hercules, CA, USA) and visua-
lized on X-ray ﬁlms. Densitometry was analyzed by
ImageJ software (National Institutes of Health,
Bethesda, MD, USA). The density of speciﬁc bands of
Western blot was then normalized to corresponding
loading control bands.
Calcium fluorometry in vitro
The change in intracellular calcium concentration
induced by the activation of NMDA receptors is import-
ant for neuron hyperexcitation. The concentration of
intracellular calcium was thus evaluated using the visible
light-excitable calcium indicator kits on neuroblastoma
cell line SH-SY5Y cells, which are undiﬀerentiated
human-derived neuroblastoma cell line. SH-SY5Y cells
of passage 10–12 were seeded onto polystyrene plates
pre-coated with 0.01% collagen (MilliporeSigma), with
a plating density of 6 104 cells/well. Cells were main-
tained in 100 ml Dulbecco’s modiﬁed eagle medium
(Thermo Fisher Scientiﬁc, Waltham, MA, USA) con-
taining 10% fetal bovine serum (Thermo Fisher
Scientiﬁc) and 1% penicillin-streptomycin-fungizone (P/
S, Thermo Fisher Scientiﬁc). SH-SY5Y cells were kept in
an incubator with humidiﬁed atmosphere and 5% CO2
at 37C. After 24 h, Fluo-4 NW calcium dye (Thermo
Fisher Scientiﬁc) was used to monitor the alteration of
intracellular calcium concentration according to the
manufacturer’s instruction. Cells were divided into
seven groups including (1) three stimulation groups in
which cells were stimulated by NMDAR agonists
NMDA and glycine (NG group) or with 1 h pre-incuba-
tion of 3 mM of propofol (MilliporeSigma; P3þNG
group) or 10 mM of propofol (P10þNG group), (2)
two propofol groups without NMDAR stimulation in
which cells were incubated with 3 mM of propofol (P3
group) or 10 mM of propofol (P10 group), and (3) two
control groups in which cells had no treatment as a nega-
tive control group or were stimulated with 5 mM of
Ionomycin (Thermo Fisher Scientiﬁc), which induced a
maximal calcium inﬂux as a positive control group. The
two concentrations of propofol 3 mM and 10 mM were
approximately equivalent to propofol blood concentra-
tion that have been reported at 2 h and 30min after infu-
sion in rats.31 The intracellular calcium concentration
was detected by micro-plate reader (Thermo Fisher
Scientiﬁc) with 494 nm excitation wavelength, 12 nm
excitation bandwidth, and 519 nm emission wavelength.
All data were recorded after the administration of 30 mM
of NMDA receptor agonist NMDA (MilliporeSigma)
and 15 mM of co-agonist glycine (MilliporeSigma) imme-
diately by SkanIt software (Thermo Fisher Scientiﬁc).
The ﬁnal data were normalized relative to Ionomycin.
Immunofluorescence staining
Animals were deeply anesthetized with sodium pentobar-
bital and perfused transcardially with ice-cold 0.9%
saline followed by 4% paraformaldehyde in 0.1M phos-
phate buﬀer. Lumbar spinal segments L3–L5 were col-
lected and post-ﬁxed in 4% paraformaldehyde and then
dehydrated overnight in 30% sucrose at 4C. The tissues
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were frozen in tissue freezing medium and sliced trans-
versely at 15 mm using a cryostat (Leica Microsystem,
Wetzlar, Germany). The sections were then blocked
with 10% normal goat serum in phosphate-buﬀered
saline (PBS) at room temperature for 1 h and followed
by incubation with primary antibody(s), including mouse
anti-c-Fos (1:100, Abcam, Cambridge, UK) mixed with
rabbit anti-NeuN antibody (1:500, Abcam), rabbit
anti p-ERKantibody (1:100, Cell Signaling Technology)
mixed with mouse anti-NeuN antibody (1:500, Abcam)
at 4C for overnight. After washing with PBS, the sec-
tions were incubated with ﬂuorescent-conjugated
secondary antibodies (1:1000, goat anti-mouse IgG con-
jugated with Alexa Fluor 488 or 568 and goat anti-rabbit
IgG conjugated with Alexa Fluor 568 or 488, Thermo
Fisher Scientiﬁc Corporation). The sections were
mounted with mounting medium with 40,6-diamidino-2-
phenylindole, dihydrochloride (DAPI) (Vector
Laboratories, Burlingame, CA, USA). The immunoreac-
tive cells were identiﬁed under a confocal microscope
(LSM 780, Carl Zeiss, Oberkochen, Germany) and posi-
tive labeled cells were counted and expressed as a percent
of total cells under the same ﬁelds.
Statistical analysis
All data in this study are expressed as mean standard
error of the mean. Calculations were performed by
GraphPad Prism software (GraphPad software Inc, La
Jolla, CA, USA). Data of time course of recovery times
were analyzed using two-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparisons
test, while other data were analyzed by one-way
ANOVA followed by Dunnett’s multiple comparisons
test. P values less than 0.05 were considered as statistic-
ally signiﬁcant.
Results
Propofol administrated before formalin challenge
reduces nociceptive responses
Changes in nociceptive response following formalin
injection. Consistent to previous reports,32,33 bi-phasic
nociceptive responses including an early phase (0–
10min and a late phase) (15–60min) was induced after
subcutaneous injection of 2.5% formalin into the hind
paw (Figure 1(a)). In the Formalin group, the rats dis-
played pain-related behaviors including hind paw lifting,
ﬂinching, and licking. In the early phase, pain scores
increased in 5min and quickly returned to baseline in
10-min post-injection. Although in the late phase, pain
scores gradually increased and peaked at 25–35min
before returning to baseline in 60min post-injection
(Figure 1(a)).
Preventive analgesic effects of propofol on inflammatory pain
induced by formalin. As shown in Figure 1(a), the increased
pain scores induced by formalin were signiﬁcantly
reduced by pre-emptive infusion of propofol in both
Group P-30min and Group P-2 h.
Firstly, in the early phase, the pain score in the
P-30min propofol treatment group was signiﬁcantly
lower than that in the Formalin group (0.41 0.09 vs.
0.79 0.07, P¼ 0.0109, n¼ 5). Secondly, in the late
phase, the rats displayed a slow response to formalin
challenge with a 10-min delay (Figure 1(b)). The time
to reach peak sensitization after injection in P-30min
and Formalin groups were 30 2 and 39 1min
(P¼ 0.007, n¼ 5), respectively. Thirdly, P-30min group
showed a signiﬁcant reduction in peak pain scores
(Figure 1(c)). The peak pain scores summarized in the
period of 35–45min (P-30min group) and 25–35min
(Formalin group) post-formalin injection were
0.43 0.05 and 0.93 0.07 (P< 0.0001, n¼ 5), respect-
ively. Last but not least, pre-emptive treatment of pro-
pofol signiﬁcantly prolonged the duration of low
sensitivity (i.e. the time when animals showed pain
scores below 30% of the peak score induced by formalin)
and reduced the duration of high sensitivity (i.e. the time
when animals showed pain scores above 60% of the peak
score induced by formalin, Figure 1(d)). Durations
below 30% of maximum in P-30min and Formalin
groups were 39 6min versus 23 3min (P¼ 0.0352,
n¼ 5) and that above 60% of maximum were 3 7
versus 26 4min (P¼ 0.0023, n¼ 5). However, there
was no signiﬁcant diﬀerence between P-30min and
Formalin groups during 30–60% of maximum (18 7
and 11 3min, P¼ 0.4619, n¼ 5, Figure 1(d)).
In contrast to P-30min group, P-2 h treatment in the
P-2 h propofol treatment group did not show signiﬁcant
eﬀect on pain scores induced by formalin in the early
phase (P-2 h versus Formalin: 0.84 0.08 versus
0.79 0.07, P¼ 0.9140, n¼ 5, Figure 1(a)).
Nevertheless, in the late phase, the pain scores in P-2 h
group were lower than that in Formalin group at 25, 30,
and 35min after formalin injection (P< 0.001, n¼ 5).
Rats in P-2 h group also displayed a slow response to
formalin challenge (Figure 1(b)). The time to reach the
peak sensitization after formalin injection in P-2 h
and Formalin groups were 40 2 and 30 2min
(P¼ 0.0035 n¼ 5), respectively. Moreover, rats in P-2 h
group also showed a signiﬁcant reduction on pain scores
at the peak of sensitization (Figure 1(c)). The peak pain
scores summarized during 25–35min after formalin
injection in P-2 h and Formalin group were 0.40 0.07
and 0.93 0.07 (P< 0.0001, n¼ 5), respectively. Similar
to P-30min group, pre-emptive treatment of propofol in
P-2 h group also signiﬁcantly increased the duration of
low sensitivity and decreased the duration of high sensi-
tivity (Figure 1(d)). Durations below 30% of maximum
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in P-2 h and Formalin groups were 38 6 and 23 4min
(P¼ 0.05, n¼ 5) and the periods above 60% of max-
imum were 11 4 and 26 4min (P¼ 0.05, n¼ 5),
respectively.
Taken together, these results demonstrated that
intravenous propofol administrated before formalin
challenge (pre-emptively) reduced formalin-induced
nocifensive behaviors in both duration and intensity.
It is worth noticing that this analgesic eﬀect of
propofol lasted for at least 2 h after propofol
administration.
Propofol inhibits the expression of spinal phosphory-
lated GluN2B induced by formalin injection
Spinal GluN2B subunit-containing NMDA receptors
play an important role in central sensitization in noci-
ceptive processing,14 which might be a potential target of
propofol under its antinociceptive eﬀect in this
inﬂammatory pain model. We thus detected the expres-
sion of phosphorylated and pan-GluN2B in the spinal
dorsal horn following formalin injection with pre-treat-
ment of propofol. As shown in Figure 2, the expression
of phosphorylated GluN2B was signiﬁcantly increased in
the ipsilateral spinal dorsal horns after formalin injection
compared to that in Naive group (1.83 0.16 versus
0.85 0.06, P¼ 0.001, n¼ 5). Interestingly, pre-emptive
treatment of propofol prevented the formalin-induced
activation of spinal GluN2B in both P-30min and
P-2 h groups (P-30min, P-2 h versus Formalin:
0.73 0.13, 0.92 0.10 versus 1.83 0.16, P¼ 0.0003,
n¼ 5, Figure 2). In contrast, there was no detectable
diﬀerence in the contralateral dorsal horns among all
the groups (Figure 2). These results indicate that propo-
fol reduces nocifensive behaviors caused by formalin via
preventing the activation of GluN2B subunit-containing
NMDA receptors in the spinal cord dorsal horn in the
inﬂammatory pain animal model.
Figure 1. Propofol reduced formalin-induced nocifensive reflexes. Time courses of pain score in Formalin group and two propofol
groups P-30 min and P-2 h after formalin injection (a), time of sensitization at peak (b), pain score at peak (c), and duration of low, medium,
and high sensitivity (i.e., the time when animals showed pain scores below 30%, 30%–60%, and above 60% of the peak score induced by
formalin) (d) were illustrated. *P< 0.05, **P< 0.01: P-30 min group versus Formalin group; #P< 0.05, ##P< 0.01: P-2 h group versus
Formalin group; n¼ 5. (a) Two-way ANOVA followed by Tukey’s multiple comparisons test. (b) to (d) One-way ANOVA followed by
Dunnett’s multiple comparisons test.
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Propofol inhibits the calcium influx induced by NMDA
receptor agonists in SH-SY5Y cells
We further identiﬁed whether calcium inﬂux through
NMDA receptors could be altered by pre-treatment
with propofol in vitro. It was found that pre-emptive
treatment with 3 mM of propofol for 1 h signiﬁcantly
reduced the calcium ﬂuorescence intensity evoked by
NMDA receptor agonists NMDA and glycine
(P3þNG versus NG: 9.58 4.70 versus 20.11 4.04,
P¼ 0.017 n¼ 9, Figure 3(a)). Similarly, 10 mM of pre-
emptive propofol also diminished the elevation of intra-
cellular calcium caused by NMDA receptor agonists
(P10þNG versus NG: 4.15 2.19 versus 18.73 2.57,
P¼ 0.0012, n¼ 13, Figure 3(b)). Thus, these results
in vitro conﬁrmed that pre-emptive propofol inhibits
NMDA receptor activation and subsequently reduces
the calcium inﬂux.
Propofol inhibits the activation of spinal MAPKs
ipsilateral to formalin challenge
Since accumulating evidence showed that MAPK signal-
ing pathways contribute to pain sensitization after nerve
injury and inﬂammation,21,34,35 the role of MAPK cas-
cades in the pre-emptive antinociceptive eﬀects of propo-
fol was further investigated. As shown in Figure 4(a),
following formalin injection, phosphorylated ERK1/2
(p-ERK1/2) protein level was elevated in the ipsilateral
dorsal horn compared with that in Naive group
(Formalin versus Naı¨ve—for ERK1: 1.19 0.07 versus
0.60 0.10, P¼ 0.0059, n¼ 5; for ERK2: 1.21 0.04
versus 0.82 0.05, P¼ 0.0017, n¼ 5, Figure 4(a)),
which was blocked by pre-emptive treatment of propofol
in both P-30min and P-2 h groups (P-30min, P-2 h,
versus Formalin—for ERK1: 0.67 0.14, 0.71 0.15,
versus 1.19 0.07, P¼ 0.0145, n¼ 5; for ERK2:
0.91 0.09, 0.95 0.04, versus 1.19 0.07, P¼ 0.029,
n¼ 5, Figure 4(a)). There was no statistical diﬀerence
in ERK activation on the contralateral sides among all
the treatment groups (Figure 4(a)).
An increase in the activation of p38 MAPK was found
following formalin injection in the ipsilateral spinal
dorsal horn. This elevated phosphorylated p38 MAPK
(p-p38) was not altered by pre-emptive treatment of pro-
pofol (Formalin versus Naı¨ve: 1.22 0.06 versus
0.81 0.07, P¼ 0.0393, n¼ 5, Figure 4(b)). Unlike
ERK1/2 and p38 MAPK, phosphorylated JNK (p-
JNK) was neither altered by formalin nor propofol
pre-treatment (Figure 4(c)). These results showed that
only ERK activation in the MARK cascades was
involved at the spinal level in the pre-emptive antinoci-
ceptive eﬀect of propofol in this inﬂammatory pain
model.
Figure 3. Propofol blocked NMDA receptor-mediated calcium
influx in vitro. In each group, fluorescence responses were nor-
malized to maximal calcium fluorescence induced by Ionomycin.
The effects of pre-emptive 3mM (a) and 10mM (b) propofol were
illustrated. *P< 0.05, **P< 0.01 versus NG group, n¼ 13, one-way
ANOVA followed by Dunnett’s multiple comparisons test.
P3: 3 mM of propofol; NG: NMDA and glycine; P3þNG: pre-
treatment with 3mM of propofol for 1 h followed by NMDA and
glycine; P10: 10mM of propofol; P10þNG: pre-treatment with
10 mM of propofol for 1 h followed by NMDA and glycine.
Figure 2. Protein expression of phosphorylated GluN2B (p-
GluN2B) and pan-GluN2B in spinal dorsal horns of L3–L5. Relative
intensity of p-GluN2B to pan-GluN2B in ipsilateral and contralat-
eral dorsal horns was illustrated. *P< 0.05, **P< 0.01 versus
Formalin group, n¼ 5, one-way ANOVA followed by Dunnett’s
multiple comparisons test.
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Propofol suppresses the neuronal expression of c-Fos
and p-ERK induced by formalin challenge in spinal
dorsal horn
To further examine whether propofol produces its pre-
ventive analgesic eﬀect through directly modulating the
neuronal activity in this inﬂammatory pain model,
double immunoﬂuorescence labeling was used to identify
the neuronal activity in the spinal dorsal horn following
formalin injection. As shown in Figure 5(a), formalin
injection induced a signiﬁcant increase in c-Fos-labeled
cells (15.19% 2.47, n¼ 3, P< 0.05) compared to that in
the Naive group (3.44% 0.56, n¼ 3). Interestingly,
these c-Fos-positive cells were co-expressed with the
neuronal marker NeuN (Figure 5(a) to (b)), suggesting
Figure 4. Protein expression of phosphorylated or pan-ERK1/2, p38 MAPK, and JNK in dorsal horn of L3–L5. Relative intensity of
phosphorylated MAPKs to pan MAPKs is shown in the graphs. Ipsilateral and contralateral ERK1/2 (a), ipsilateral p38 MAPK (b), and JNK
(c) were illustrate. *P< 0.05, **P< 0.01 versus Formalin group, n¼ 5, one-way ANOVA followed by Dunnett’s multiple comparisons test.
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that these c-Fos-labeled cells are neuronal soma. These
double-labeled cells were predominantly distributed in
the superﬁcial laminae of lumber spinal dorsal horn
(Figure 5(a) to (b)). However, the formalin-induced
increase in c-Fos/NeuN double-labeled cells were
reduced by pre-emptive treatment of propofol in both
P-30min (3.11% 1.21, P< 0.05, n¼ 3, Figure 4(a) to
(c)) and P-2 h groups (3.82% 0.65, P< 0.05, n¼ 3,
Figure 5(a) to (d)).
Furthermore, it was also found that the number of p-
ERK immunoreactive cells increased after formalin
injection, and these p-ERK-positive cells were also
double labeled with the NeuN-positive cells, indicating
that ERK is primarily activated in dorsal horn neurons
located primarily in the superﬁcial laminae of lumber
spinal dorsal horn (Figure 5(b)). As shown in Figure
5(b), formalin induced a robust increase in the double-
labeled p-ERK/NeuN-labeled cells (68.76% 3.77,
n¼ 3, P< 0.05, Figure 5(b)) compared with the Naive
group (11.74% 2.59, n¼ 3), whereas pre-emptive treat-
ment with propofol signiﬁcantly reversed this increase
in both P-30min (11.87% 2.67, n¼ 3, P< 0.05,
Figure 5(b) to (c)) and P-2 h groups (14.28% 1.83,
n¼ 3, P< 0.05, Figure 5(b) to (d)). Given that the acti-
vation of ERK in superﬁcial spinal dorsal horn after
noxious stimulation or inﬂammation is speciﬁcally essen-
tial for the induction of central sensitization,36,37 activa-
tion (phosphorylation) of ERK in dorsal horn neurons
has been served as a marker for central sensitization.
Thus, these results show that pre-emptive propofol infu-
sion produces its preventive analgesic eﬀect on formalin-
induced inﬂammatory pain via suppressing of neuronal
p-ERK activation and central sensitization in the lumbar
spinal dorsal horn.
Discussion
This study demonstrates that intravenous infusion of
propofol before inﬂammatory (formalin) challenge pro-
duces preventive analgesic eﬀects characterized by a
delayed response to formalin and a reduction in hyper-
sensitivity. This preventive analgesic property of propo-
fol appears to be attributed to its inhibitory eﬀects on
calcium inﬂux through NMDA receptor and the down-
stream molecules of ERK1/2 MAPKs in the spinal
dorsal horn neurons.
While clinical studies have reported that surgical
patients receiving propofol-based anesthesia intraopera-
tively experienced less postsurgical pain,38–40 the ﬁndings
from clinical and pre-clinical studies vary widely from
analgesic eﬀect,5,9 no analgesia,7 or hyperalgesia.8
Animal studies reported that topical or intrathecal pro-
pofol produced antinociceptive eﬀects on heat-evoked
responses41 or antihyperalgesic eﬀect on formalin-
induced pain,42 whereas intravenous infusion of
propofol showed no analgesia on the second phase of
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Figure 5. Distribution and co-localization of c-Fos-positive and p-ERK-positive-labeled neurons in the spinal cord dorsal horn following
different treatment groups, including Naive group without any treatment (Naı¨ve), formalin treatment group with formalin injection only
(Formalin), and formalin injection with pretreatment of propofol followed by a recovery time of 30 min (P-30 min) or 2 h (P-2 h). (a)
Confocal fluorescence images illustrate the co-localization of c-Fos-positive cells (red), NeuN (green), and DAPI (blue) in the different
treatment groups. (b) Confocal fluorescence images illustrate the co-localization of p-ERK-positive cells (red), NeuN (green), and DAPI
(blue) in the different treatment groups. Dotted lines show the estimated edges of laminae I. Scale bar: 50mm. The column figures on the
right panel show the summary data following different treatments. *P< 0.05, n¼ 3, one-way ANOVA on ranks followed by Dunn’s post
hoc test.
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formalin-induced nocifensive responses.43 Even in the
same rat model of formalin-induced inﬂammatory
pain, Merrill et al.6 reported that propofol lacks anal-
gesic property because it does not prevent the formalin-
induced Fos-like expression, a neuronal marker for
noxious stimulation. However, Gilron et al.44 found
that when given pre-emptively before formalin injection,
propofol did suppress the formalin-induced spinal Fos-
like immunoreactivity, suggesting its important analgesic
property of propofol. Apparently, not only does the
stimulus nature but more notably the administration
timing of propofol, e.g., pre- versus post-formalin injec-
tion, plays a role in the discrepant results.
Pre-emptive analgesia given before surgery has been
widely used as an analgesic strategy to reduce postsurgi-
cal pain severity and duration and even prevent the
development of postsurgical chronic pain.45 Recent
study found that pre-emptive single dose of intravenous
propofol decreased post-surgical analgesia requirements
compared with ketamine or remifentanil.9 Inﬂammatory
pain is the most common sequela after surgery due to
tissue injury and tissue injury induced release of inﬂam-
matory mediators.28 This study, for the ﬁrst time using
the well-established inﬂammatory pain model induced by
formalin and adopting the same modality used in clinical
administration (i.e. TIVA) by intravenous infusion of
propofol at a dose of 0.6mg kg1min1 (the equivalent
human dosage 0.1 mg kg1min1 for maintenance of
general anesthesia calculated according to a guide for
dose conversion between animals and human46), evalu-
ated whether pre-emptive propofol could prevent the
development of hyperalgesia following inﬂammatory
pain.
Consistent with previous report,30 the biphasic noci-
fensive reﬂexes were found after intra-plantar injection
of formalin in this study, including an early phase
(0–10min) and a late phase (15–60min), which reﬂect
the direct activation of nociceptors and spinal neuronal
sensitization with functional alteration, respectively, fol-
lowing formalin injection.44,47 There are several evi-
dence-based ﬁndings in this study. First, propofol
infusion resulted in preventive analgesic eﬀect on forma-
lin challenge even though it was stopped for 30min to 2 h
when its anesthetic eﬀect disappeared. Second, compared
to the P-30min group in which propofol produced anti-
nociceptive eﬀect on both early and late phases, propofol
treatment with 2 h recovery time exhibited pain relieving
eﬀect only on the late phase while leaving the early phase
unaﬀected. This ﬁnding is supported by Takechi’s report
that topical application of propofol suppressed noxious
heat-evoked responses maximally at 15min after appli-
cation and its antinociceptive eﬀect was faded within
30min.41 In the same model of formalin-induced inﬂam-
matory pain, single bolus of pre-emptive propofol
administration (5–20mg kg1) before formalin injection
showed pain relief in the early phase but not in the late
phase.43 The reason is likely that single bolus of propofol
(10mg kg1) loses its eﬀect quickly (in 4min)48 so that its
action may be transient only in the peripheral nervous
system. In the present study, intravenous perfusion of
propofol for 1 h led to preventive analgesia in both
early and late phases of the formalin pain model, indicat-
ing that propofol may need longer time to exert its anal-
gesic eﬀect through modulating the neuronal excitability
and responsiveness in the central nervous system such as
suppressing the spinal dorsal neuronal c-Fos expression
and ERK1/2 activation. Finally, the present study
showed that the rats in both P-30min and P-2 h groups
displayed a slow hypersensitization to formalin chal-
lenge, less pain severity, and a shorter duration of experi-
encing hypersensitization. These eﬀects exhibiting in the
P-2 h group indicate that the preventive analgesic prop-
erty of propofol can last for at least 2 h after infusion in
this animal model of inﬂammatory pain.
It is well known that NMDA receptors play critical
roles in generating and mediating nociceptive signal
transmission and central sensitization at the spinal cord
level.49 Intrathecal injection of NMDA receptor agonist
is associated with a signiﬁcant increase in phospho-
Tyr1472 GluN2B, whereas no changes were observed in
pan-GluN2B expression during inﬂammatory pain.14,50
Additionally, gene knockdown of GluN2B expression
relieved formalin-induced nociception in the late phase
in rats.51,52 In concordance with behavioral results, pro-
pofol infusion with 30min or 2 h recovery periods sig-
niﬁcantly reduced the expression of phosphorylated
GluN2B in the ipsilateral spinal dorsal horn, whereas
no change was found on the contralateral side. The ﬁnd-
ings of the antinociceptive eﬀect of pre-emptive propofol
(at least 2 h after the infusion) may help to explain the
clinical ﬁndings that administration of propofol during
operations shows superior eﬃcacy in management of
postoperative pain as compared with other inhalational
anesthetics.38–40 Furthermore, given the fact that the
activation of synaptic GluN2B in nociceptive neurons
can result in calcium inﬂux and a variety of calcium-
mediated cascades that subsequently induce augmenta-
tion of neuronal excitability and hypersensitivity to per-
ipheral stimuli,16 our ﬁndings that NMDA receptor-
mediated calcium inﬂux was signiﬁcantly inhibited by
pre-incubation with either 3 mM or 10 mM of propofol
for 1 h in SH-SY5Y cells provide the ﬁrst evidence
in vitro that pre-treatment with propofol inhibits calcium
inﬂux through GluN2B-containing NMDA receptor.
ERK1/2 is one of the downstream eﬀectors of
GluN2B receptor in the postsynaptic neurons in spinal
dorsal horn,53 and ERK1/2 activation induced by nox-
ious stimulus can be reduced by NMDA receptor block-
ers.36 Activation of ERK1/2 was enhanced after formalin
challenge in the spinal dorsal horn neurons, whereas the
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inhibition of ERK1/2 reduced nociceptive response in
the late phase of formalin test.54 Consistent with previ-
ous reports,36,55 we found that phosphorylation ERK
(p-ERK1/2)-labeled neurons were increased in the super-
ﬁcial dorsal horn after formalin injection, which was sup-
pressed by pre-emptive propofol infusion in both groups
with 30min and 2 h recovery periods. These ﬁndings
indicate that pre-emptive propofol-induced reversal of
the activation of ERK1/2 induced by formalin in ipsilat-
eral dorsal horn contributes to the delayed sensitization
and reduced hypersensitivity in inﬂammatory pain. This
feature of propofol is most likely associated with its
inhibitory eﬀect on pain hypersensitivity induced by
ERK1/2 activation as intrathecal injection of the MEK
inhibitor PD 98059, which blocks ERK phosphoryl-
ation, dose-dependently reduced the late phase of pain
response without changing the early phase following for-
malin injection.36 Additionally, though formalin induced
an increase in p38 MAPK expression compared with that
in the Naive group, propofol had no eﬀect on the acti-
vation of p38 MAPK in formalin-induced inﬂammatory
pain model (Figure 6). Unlike ERK1/2, p38 MAPK is
mainly activated by cytokines after inﬂammation.36 The
current ﬁndings indicate that the analgesic property of
propofol may not be directly associated with its anti-
inﬂammatory eﬀect.56
Finally, c-Fos has been used as a neuronal marker to
study nociception with its rapid expression characterisitc
in neurons in response to various nociceptive stimuli.57
A consistency with previous reports was observed in the
current study in c-Fos expression and distribution in the
superﬁcial spinal dorsal horn after formalin stimula-
tion.4,6,44 Also, in accordance with previous reports
that propofol directly suppressed lumber dorsal
horn neuronal responses to noxious stimulation,58 the
current ﬁndings in propofol suppressing the increased
c-Fos-/NeuN-positive neurons is paralleled with the
behavioral ﬁndings lasted up for 2 h. Thus, propofol
at an anesthetic dose inhibits the activity of these projec-
tion neurons in the superﬁcial laminae of the spinal
dorsal horn and subsequently suppresses the develop-
ment of central sensitization and blocks nociceptive
transmission.
There are clinical implications and limitations for this
study. While propofol alone is not encouraged to be used
for analgesia in clinical practice because of controversy
under diﬀerent surgical circumstances,59,60 its pre-emp-
tive analgesic property when used as an anesthetic for
maintenance of general anesthesia could be an advantage
to manage postsurgical pain as compared to other inha-
lational anesthetics, e.g., isoﬂurane has recently been
reported to impair cognition by increasing the extrasy-
naptic expression of GluN2B in rat hippocampus.61
Moreover, with the preventive analgesic eﬀects of pro-
pofol shown, it can potentially contribute to the
multimodal analgesia with other analgesics to better con-
trol acute postsurgical pain.
In conclusion, intravenous infusion of propofol admi-
nistrated pre-emptively attenuated formalin-induced
inﬂammatory pain. This preventive analgesic eﬀect
of propofol appears to be mediated by spinal neuronal
GluN2B-containing NMDA receptor and ERK1/2
MAPK pathway. The current ﬁndings provide evi-
dence-based molecular and cellular support, at the
spinal level, for the potential preventive analgesia of
propofol in the perioperative management of post-
surgical pain.
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